<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04787705</url>
  </required_header>
  <id_info>
    <org_study_id>18-5588</org_study_id>
    <nct_id>NCT04787705</nct_id>
  </id_info>
  <brief_title>Multicenter Validation of a Predictor Model of ACHD Patients and Cardiac Surgery</brief_title>
  <official_title>Novel Model of Preoperative Predictors of Outcome for Adults Undergoing Congenital Cardiac Surgery: Multicenter Model Validation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Providence Healthcare</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Montreal Heart Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Westmead Hospital, Sydney, New South Wales, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Prince Charles Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Auckland City Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mater Misericordiae University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Newcastle-upon-Tyne Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multicentre study is to validate prediction modeling for the ACHD population undergoing&#xD;
      cardiac surgery. The validation of this prediction model will support and generalize its use&#xD;
      as a risk stratification tool in the ACHD population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prediction model resulted from a preceding study, which uniquely based on comorbidities,&#xD;
      was developed using 783 adults (&gt;16 years) who underwent surgery for congenital heart disease&#xD;
      at Toronto General Hospital (TGH) during 2004-2015. It identifies five pre-operative&#xD;
      variables, namely presence of cognitive impairment, hepatic function, &gt;3 chest incisions,&#xD;
      anatomy diagnosis, and Body Mass Index &lt;20 and &gt;28, as significant predictors of composite&#xD;
      adverse outcomes such as in-hospital mortality, prolonged ventilation (exceeding 7 days) and&#xD;
      acute kidney injury.&#xD;
&#xD;
      This newly prediction model developed in a single-center has only been internally validated.&#xD;
      It requires further external validation to demonstrate its utility in ACHD populations who&#xD;
      require cardiac surgery in other cardiac institutions both nationally and internationally.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 10, 2020</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Composite adverse events</measure>
    <time_frame>30 days from the day of surgery.</time_frame>
    <description>The composite adverse outcome is defined by in-hospital mortality, prolonged ventilation (exceeding seven days), or acute kidney injury requiring dialysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>One-year mortality</measure>
    <time_frame>365 days from the day of surgery.</time_frame>
    <description>One-year is defined as 365 days from the day of surgery.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Adult Congenital Heart Disease</condition>
  <condition>Cardiac Surgery</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All ACHD patients undergoing cardiac surgery in TGH and the other collaborating cardiac&#xD;
        centers.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  all ACHD patients &gt;16 years of age undergoing cardiac surgery requiring an open&#xD;
             sternotomy or thoracotomy and cardiopulmonary bypass (CPB) or CPB standby at TGH and&#xD;
             the collaborating institutions from April 2019.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  CHD patients &lt;16 years of age&#xD;
&#xD;
          -  ACHD patients undergoing chest wall debridement and chest re-explorations for bleeding&#xD;
&#xD;
          -  Non-cardiac surgery procedures and cardiology laboratory interventions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jane Heggie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jane Heggie, MD</last_name>
    <phone>(416) 340-3567</phone>
    <email>jane.heggie@uhn.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jo Carroll</last_name>
    <phone>416-340-4800</phone>
    <phone_ext>3243</phone_ext>
    <email>jo.carroll@uhn.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Toronto General Hospital - University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Heggie, MD</last_name>
      <phone>(416) 340-3567</phone>
      <email>jane.heggie@uhn.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 2, 2021</study_first_submitted>
  <study_first_submitted_qc>March 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2021</study_first_posted>
  <last_update_submitted>March 5, 2021</last_update_submitted>
  <last_update_submitted_qc>March 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prediction model</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

